Tag:

Personalized Medicine

Health

New Wearable Microneedle Patch Monitors Drug Levels in Real Time

by Chief Editor
written by Chief Editor

Researchers at King Abdullah University of Science and Technology (KAUST) have developed a wearable microneedle patch capable of continuously measuring drug concentrations in interstitial fluid and transmitting that data to a smartphone in real time. The device, which weighs 6.7 grams, aims to explore whether continuous monitoring could provide a more complete picture than periodic blood tests for medicines that require careful dosing, such as the antibiotic vancomycin.

Moving Beyond Periodic Blood Draws

Current medical standards for monitoring many medicines that require careful dosing rely on periodic blood tests. These laboratory analyses provide a single data point, offering only a snapshot of how a drug is behaving in a patient’s system at one specific moment. According to the study published in Device, these tests can take time to process.

The KAUST platform shifts this paradigm by utilizing an array of tiny microneedles that access interstitial fluid—the fluid surrounding the cells just beneath the skin. By integrating electrochemical biosensors with miniaturized electronics and Bluetooth connectivity, the device tracks drug levels continuously. This provides a comprehensive view of how a therapeutic agent moves through the body over time, rather than relying on delayed laboratory results.

Did you know?

The prototype developed by the KAUST team weighs only 6.7 grams. It manages to pack microneedle sensing, electrochemical biosensors, onboard electronics, and wireless communication into one wearable unit.

Testing Precision with Vancomycin

To validate the platform, the research team focused on vancomycin. This antibiotic is a critical choice for testing because the drug must be maintained within a relatively narrow concentration range to remain both safe and effective against serious infections.

Khaled Nabil Salama, professor of Electrical and Computer Engineering and Bioengineering at KAUST and lead author of the study, noted that the technology demonstrates a new approach to therapy monitoring. During laboratory and preclinical experiments, the device successfully tracked changing drug concentrations over several hours. The findings suggest that while currently demonstrated with an antibiotic, the platform could be adapted for other medicines requiring careful dose monitoring.

The Path Toward Clinical Integration

While the initial results are promising, the technology remains in an early stage of development. Before the device can be used in healthcare settings, it must undergo further development and clinical validation to ensure accuracy and long-term stability.

AUC-Based Vancomycin Monitoring Does Not Result in Higher Total Costs for MRSA Bacteremia

Future research efforts will focus on three key areas: extending the duration of the monitoring sessions, improving the long-term stability of the sensors, and evaluating the system across a broader range of medical applications. This work aims to support more personalized approaches to treatment for patients who require careful dose monitoring of their medication levels.

Frequently Asked Questions

How does the microneedle patch measure drug levels?
The device uses an array of tiny microneedles that access interstitial fluid beneath the skin. Electrochemical biosensors then measure the concentration of the drug and transmit the data via Bluetooth to a smartphone.
Why is continuous monitoring better than blood tests?
Periodic blood tests only provide a snapshot of drug levels at a single moment. Continuous monitoring, according to KAUST researchers, offers a more complete picture of how a medicine moves through the body over time.
Is this technology ready for use in hospitals?
Not yet. The researchers state that further development and clinical validation are required before the platform can be used in healthcare settings.

Stay Informed

Want to track the latest breakthroughs in medical wearable technology? Subscribe to our newsletter for updates on how digital health tools are evolving. Have questions about the future of personalized medicine? Leave a comment below to join the conversation.

0 comments
0 FacebookTwitterPinterestEmail
Health

New Blood Test Predicts Chemotherapy Benefit for Colorectal Cancer

by Chief Editor
written by Chief Editor

A personalized blood test measuring circulating tumor DNA (ctDNA) can identify colorectal cancer patients who benefit most from adjuvant chemotherapy after liver metastasis surgery. According to the Phase II GALAXY study presented at the ESMO Gastrointestinal Cancers Congress 2026, patients with detectable ctDNA after surgery saw overall survival rates of 65% with chemotherapy, compared to 33% without it.

How ctDNA Testing Influences Post-Surgical Care

The GALAXY study, led by researchers from Hyogo Medical University and the University of Oxford, tracked 298 patients to determine if molecular markers could predict recurrence. For those who underwent upfront surgery, the presence of ctDNA was a critical indicator of risk. Patients with detectable ctDNA faced more than four times the risk of cancer recurrence and more than nine times the risk of death compared to those who tested negative.

How ctDNA Testing Influences Post-Surgical Care

The data suggests a clear path for treatment selection. Among the 191 patients who underwent upfront surgery, those with detectable ctDNA experienced a 93% reduction in the risk of recurrence when treated with adjuvant chemotherapy. Conversely, patients without detectable ctDNA showed favorable long-term outcomes regardless of whether they received subsequent chemotherapy.

Did you know?

Colorectal cancer is the third most common cancer worldwide and the second leading cause of cancer death, with the liver serving as the most common site of metastatic spread.

Why Current Treatment Protocols May Change

Current clinical practice often involves administering chemotherapy to patients following surgery to address potential microscopic cancer cells. However, Per Pfeiffer, MD, PhD, professor of oncology at Odense University Hospital, notes that only about 1 in 10 patients is cured by this adjuvant therapy, even as nearly all experience treatment-related side effects.

GALAXY: ctDNA dynamics and adjuvant chemotherapy in colorectal cancer

The study highlights a distinct difference in outcomes based on when surgery occurs. In that specific subgroup, additional post-surgical chemotherapy provided no observable benefit, regardless of ctDNA status.

Moving Toward Precision Oncology

The potential for ctDNA to spare patients from unnecessary, toxic treatments is a primary driver of this research. By identifying which individuals are unlikely to benefit from chemotherapy, clinicians may soon be able to personalize care plans more effectively.

Despite these findings, researchers emphasize that this diagnostic approach is not yet ready for standard clinical use. According to Dr. Pfeiffer, further randomized studies are required to validate these results before ctDNA testing can be integrated into routine oncology practice outside of clinical trials.

Frequently Asked Questions

  • What is ctDNA?

    Circulating tumor DNA (ctDNA) refers to small fragments of DNA released by tumor cells into the bloodstream, which can be detected via a specialized blood test.
  • Can ctDNA testing replace chemotherapy?

    Not currently. According to researchers, the evidence is not yet strong enough for routine use, and further randomized clinical trials are necessary.
  • Who should consider this test?

    The study focused on patients with colorectal cancer that has spread to the liver. It is currently being evaluated within the context of clinical research trials.
Pro Tip:

If you are currently managing a cancer diagnosis, ask your oncologist about active clinical trials in your area. Participating in research is often the only way to access emerging diagnostic technologies like personalized ctDNA monitoring.

Are you interested in the latest developments in oncology research? Subscribe to our newsletter for updates on clinical trials and precision medicine breakthroughs.

0 comments
0 FacebookTwitterPinterestEmail
Health

Gene Test Identifies Breast Cancer Patients Who Can Safely Skip Chemotherapy

by Chief Editor
written by Chief Editor

A genomic test can identify many breast cancer patients who can safely forgo chemotherapy without increasing their risk of recurrence, according to results from the international OPTIMA trial presented at the 2026 American Society of Clinical Oncology meeting. Researchers found that patients aged 40 and over with hormone-sensitive tumors and a low Prosigna test score achieved five-year survival rates comparable to those who received chemotherapy, effectively sparing thousands of patients from unnecessary treatment-related toxicity.

How does the Prosigna test determine treatment?

The Prosigna test measures the activity of genes involved in breast cancer growth using tissue samples from surgery or diagnostic biopsies, according to the OPTIMA (Optimal Personalised Treatment of early breast cancer using Multi-parameter Analysis) research team. By analyzing these biological markers, clinicians can distinguish between tumors that require aggressive systemic treatment and those that respond sufficiently to hormone therapy alone. Lead investigator Professor Rob Stein of the University College London Cancer Institute states that the test allows medical teams to shift away from relying solely on traditional clinical features, such as tumor size or lymph node involvement, toward a model driven by tumor biology.

How does the Prosigna test determine treatment?
Did you know?
The OPTIMA trial included 4,429 patients across the UK, Norway, Sweden, Australia, New Zealand, and Thailand. Unlike previous studies that focused heavily on postmenopausal women with limited lymph node involvement, this trial included premenopausal women and those with more extensive disease.

What were the survival outcomes for patients?

Data from the trial shows that 68% of participants received a low Prosigna score, indicating a low risk of recurrence. For this specific group, the five-year survival rate was 94.9% for those who received chemotherapy and 95.1% for those who did not. According to the study’s statistical analysis, at most 2% of patients with a low score would see any benefit from chemotherapy, suggesting the treatment provides little to no additional protection for the vast majority of this population. Professor Iain MacPherson of the University of Glasgow notes that these findings provide robust, practice-changing evidence that chemotherapy use can be safely reduced.

What were the survival outcomes for patients?

Case Study: A patient’s experience with genomic testing

Karen Bonham, a 64-year-old speech and language therapist from Cardiff, was diagnosed with hormone-sensitive breast cancer in 2017. Despite standard clinical guidelines suggesting chemotherapy for her specific diagnosis—which included two affected lymph nodes—the Prosigna test results arrived just days before her scheduled treatment. Because her test indicated a low score, Bonham was assigned to the trial’s test-directed group. She avoided chemotherapy entirely, opting instead for radiotherapy and hormone therapy. Almost nine years later, Bonham remains cancer-free, attributing her quality of life to the ability to receive targeted, appropriate treatment rather than a one-size-fits-all regimen.

The OPTIMA Clinical Trial

What is the future of genomic testing in the NHS?

Healthcare bodies, including the National Institute for Health and Care Excellence (NICE), are expected to use these findings to evaluate wider access to Prosigna testing. By demonstrating the cost-effectiveness of test-directed treatment, the trial provides a pathway for the National Health Service (NHS) to reduce unnecessary chemotherapy for an estimated 5,000 patients annually. While the current results are comprehensive, researchers noted that it is not yet known if these findings apply to patients under the age of 40. The next phase of the trial is designed to generate data specifically for this younger demographic.

Pro Tip:
If you or a loved one are facing a breast cancer diagnosis, ask your oncologist if genomic testing is appropriate for your specific tumor profile. Understanding the biological activity of the cancer can often help patients and doctors make more informed decisions about the necessity of systemic therapies.

Frequently Asked Questions

  • Who is eligible for the Prosigna test? The OPTIMA trial results apply to patients aged 40 and older with hormone-sensitive breast cancer.
  • Does the test work for patients with lymph node involvement? Yes. The trial successfully demonstrated that outcomes were similar regardless of the number of affected lymph nodes.
  • Is chemotherapy always necessary for breast cancer? No. According to the OPTIMA trial, many patients with low genomic scores can safely avoid chemotherapy without compromising their survival outcomes.

Have you or a family member been affected by breast cancer treatment decisions? Share your thoughts in the comments below or subscribe to our health newsletter for the latest updates on oncology research and personalized medicine.

0 comments
0 FacebookTwitterPinterestEmail
Health

Saliva Could Flag One of SA’s Deadliest and Baffling Cancers Sooner

by Chief Editor
written by Chief Editor

The Future of Non-Invasive Diagnostics: Can a Spit Test Save Millions?

For decades, the gold standard for detecting esophageal cancer has been the endoscopy—a procedure that, while effective, is invasive, expensive, and often inaccessible to those living in rural or underserved regions. By the time a patient feels the physical struggle of swallowing, the window for curative treatment has often slammed shut.

From Instagram — related to Invasive Diagnostics, Spit Test Save Millions

However, a paradigm shift is occurring. We are moving away from “reactive” medicine toward “predictive” screening. Recent breakthroughs from the Sydney Brenner Institute for Molecular Bioscience (SBIMB) suggest that the secret to early detection isn’t hidden deep within the tissue, but is floating in our saliva.

Did you know? Saliva is more than just water; it contains electrolytes, enzymes, and epithelial cells from which DNA can be extracted, making it a goldmine for non-invasive diagnostic data ([Source]).

The Rise of the “Liquid Biopsy”

The concept of a “liquid biopsy” is transforming oncology. Instead of cutting into an organ to take a tissue sample, clinicians are looking for biomarkers—proteins, circulating tumor DNA, or microbial signatures—in bodily fluids.

The Rise of the "Liquid Biopsy"
Liquid Biopsy

The focus is now shifting toward the oral microbiome. Researchers have identified that patients with oesophageal squamous cell carcinoma (ESCC) exhibit a distinct bacterial fingerprint in their saliva. Specifically, the increased abundance of bacteria like Fusobacterium nucleatum serves as a red flag, signaling that something is wrong long before a tumor becomes visible on a standard scan.

This trend suggests a future where a simple cheek swab or saliva sample could act as a “triage tool.” Rather than putting every high-risk patient through an expensive endoscopy, doctors can use microbial screening to identify who needs urgent intervention, drastically reducing healthcare costs and patient anxiety.

AI and the “Digital Signature” of Disease

The real magic happens when we combine biology with Big Data. The human eye cannot possibly map the thousands of bacterial variations in a saliva sample, but machine learning can.

New Saliva Test for Detecting Hereditary Cancers

By using genetic sequencing and AI, scientists can now identify “microbial patterns” that correlate with specific cancers. Here’s the birth of the digital signature—a unique biological code that tells a physician not just that a disease is present, but potentially what subtype It’s and how it is progressing.

Looking forward, People can expect these AI models to integrate with wearable tech. Imagine a future where your health data is monitored continuously, and a periodic home-based saliva test syncs with an AI to alert your doctor the moment your microbial balance shifts toward a high-risk profile.

Pro Tip: While we wait for these tests to hit the mainstream, maintaining rigorous oral hygiene is key. The link between oral bacteria and systemic health is profound; regular dental check-ups are your first line of defense in monitoring the oral microbiome.

Closing the Global Health Gap

One of the most promising trends of this research is its application in “high-incidence belts.” Oesophageal cancer doesn’t strike equally; it clusters in parts of China, Iran, and Eastern Africa, often affecting people as young as 40.

Closing the Global Health Gap
South African cancer patient medical scan

In these regions, the barriers to healthcare are immense. A low-cost, saliva-based test removes the need for high-tech hospital infrastructure for initial screening. This democratizes cancer detection, moving it out of elite urban centers and into rural clinics where it is needed most.

researchers are now exploring mutation signatures. By analyzing the DNA of tumors, scientists can find “molecular fingerprints” left by environmental pollutants, smoke, or contaminated water. This allows public health officials to identify exactly what in the environment is causing the cancer, leading to targeted policy changes to prevent the disease entirely.

For more on how lifestyle changes impact long-term health, see our guide on preventative screening strategies.

FAQs: Saliva Testing and Cancer Detection

Can a saliva test replace a biopsy?
No. Currently, saliva tests are intended as triage tools. They can flag high-risk individuals who need an endoscopy, but a tissue biopsy remains the only way to definitively diagnose cancer.

Is this test available for everyone now?
Not yet. Most of this research is in the validation phase. It must be tested across different populations, diets, and geographies to ensure the “microbial signature” is universal before it enters the clinic.

What causes the bacteria in my saliva to change?
Bacteria can change due to diet, smoking, oral hygiene, and the presence of disease. In the case of ESCC, the cancer may create a “blockage” or a change in the environment of the esophagus that allows specific bacteria to flourish.

What do you think? Would you feel more comfortable with a simple saliva swab than an invasive procedure for early cancer screening? Share your thoughts in the comments below or subscribe to our newsletter for the latest updates in medical innovation.

0 comments
0 FacebookTwitterPinterestEmail